FDA IDE Approval to Initiate a Pivotal Study of the NEXUS Aortic Arch Stent Graft System Has Been Announced

Today Endospan announced they have received FDA IDE approval to initiate a pivotal study of the NEXUS Aortic Arch Stent Graft System.

NEXUS™ Aortic Arch Stent Graft System: Earlier this year, FDA granted NEXUS™ as a breakthrough device. This designation acknowledges the NEXUSTM may provide a more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.

Minimally invasive techniques are standard-of-care for treating descending aortic disease and heart disease, but highly invasive, high-mortality open surgery is still being used in the difficult-to-treat aortic arch anatomy. The NEXUSTM is uniquely engineered to address this significant area of unmet clinical need. More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% being diagnosed or treated. This global market opportunity is over $1.3 billion in a high average selling segment with no other off-the-shelf competition to the NEXUS™ technology.

The prospective and multi-arm pivotal IDE TRIOMPHE study will evaluate in up to 30 centers, the safety and effectiveness of the NEXUS™ for the endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, penetrating aortic ulcers and intramural hematoma.

“The TRIOMPHE pivotal study will assess the NEXUSTM in some of the most challenging Aortic Arch Pathologies that we encounter. For the patient, there are limited options to treat these life threatening pathologies. The NEXUSTM device is designed to address most of those complexities through a minimally invasive approach with the potential to provide a safe and durable solution,” indicated the National principal co-investigator, Dr. Ross Milner, Professor of Surgery, Co-Director, Center for Aortic Diseases at the University of Chicago.

Brad Leshnower, Associate Professor of Surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, the National principal co-investigator stated, “There are a significant number of patients who are too high risk for open surgical treatment who are also at significant risk from their aortic arch disease. The NEXUSTM provides an innovative minimally invasive option, which provides cardiac surgeons, if proven safe and effective, the potential to save the lives of patients who would have previously had no other treatment options available.”

Kevin Mayberry CEO of Endospan added, “This is a significant milestone for Endospan in bringing the NEXUSTM towards US patients. We are very encouraged by the European clinical data and commercialization of NEXUSTM in Europe. Starting a pivotal study in the U.S. brings us one step closer to our goal of providing an endovascular approach to treat aortic arch disease pathologies.”

 

SourceEndospan
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version